In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
Czech Cannabis Reform: Progress, Projections, and Politics
#cannabisindustry – ”
Over the past year, the Czech Republic has emerged as Europe’s most exciting prospect for cannabis reform and potential commercial legalisation.
In the first of a series of articles taking a deep dive into the market, focusing on everything from its progressive laws surrounding hemp to its supply chains and investment potential, Business of Cannabis will explore the current political climate in the country.
Alongside majority support for the proposed regulatory changes amongst the public, the Czech Republic has one of the most promising political landscapes in Europe with regard to cannabis reform.
While obstacles undoubtedly remain on the road to legalisation, the Czech Republic is expected to have a smoother ride than other European counterparts such as Germany, which must overcome a lack of majority in the upper house as well as the inevitable pushback internationally.”
Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes.
#cannabisresearch – “Following the discovery of various effects on skin function by modifying endocannabinoid systems, multiple preclinical studies have revealed the promise of cannabis and cannabinoids in the treatment of a variety of skin diseases. However, its clinical efficacy is still debated.
The protocol has been prepared using the Preferred Items for Systematic Review and Meta-analysis Protocols guidelines. A systematic search will be conducted using PubMed, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials and Web of Science. We will include randomised controlled trials and observational studies investigating alterations to dermatological characteristics following administration of cannabis and cannabinoids for dermatological diseases and disorders.”
Wholesale cannabis prices rise in key states, but downward pressure expected
#cannabisindustry – ““Over the course of this month, you start to see a huge buildup of inventory across the industry,” Ben Burstein, strategist at New York-based wholesale cannabis platform LeafLink, told MJBizDaily in an interview.
“You start to get huge surpluses of excess product, and at these times, especially around the harvest season, it causes big price declines.”
Data collected in 13 states by the LeafLink platform shows that after months of record-breaking lows, wholesale marijuana flower prices have stabilized in a few key, older markets such as California and Michigan.”
Cannabis Rescheduling and Trademarks
#cannabisindustry – “Cannabis rescheduling appears to be a matter of time and my colleagues have written about the possible implications (see here, here, and here). Rescheduling to a less restrictive category will also have implications for trademarking by cannabis brands. By broadening the legality of cannabis goods and services, rescheduling will also make more canna trademarks eligible for federal protection.
The U.S. Patent and Trademark Office (USPTO) will refuse the registration of any trademark used in connection with goods or services that are unlawful according to federal law. That includes all cannabis that is considered marijuana under the Controlled Substances Act (CSA), that is, all cannabis with a THC content that exceeds 0.3%. Marijuana’s inclusion in the most restrictive controlled substances schedule pretty much closes the door on any activities involving it being considered legal under federal law.
Cannabis rescheduling would change that. Per Health and Human Services’ recommendation, many commentators believe that cannabis’ new home is likely to be Schedule III. Schedule III substances are those that “have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.” According to the Drug Enforcement Administration (DEA) Diversion Control Division, Schedule III substances include “products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).””
Calif. cannabis industry panics over proposed label law
#californiacannabis – “If signed into law, AB 1207 would make it illegal to use cartoons or depictions of animals and most plants and vegetables on cannabis packaging and advertising. However, the state’s cannabis industry says the bill is written so broadly that it blocks far more than just advertising that appeals to children. They say it would, for instance, stop business owners like Senter from showing their faces on social media while promoting their products, and would block an organic cannabis farm from putting flowers on its labels.”